Send the following on WhatsApp
Continue to Chathttps://it.marketscreener.com/quotazioni/azione/HANALL-BIOPHARMA-CO-LTD-20699482/attualita/Il-secondo-inibitore-del-FcRn-di-Hanall-HL161ANS-sara-aggiunto-al-programma-di-sviluppo-del-suo-p-41940950/?utm_source=whatsapp&utm_medium=social&utm_campaign=share